Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comprehensive Cytokine Profiling of Patients with COVID-19 Receiving Tocilizumab Therapy.
Lebedeva A, Molodtsov I, Anisimova A, Berestovskaya A, Dukhin O, Elizarova A, Fitzgerald W, Fomina D, Glebova K, Ivanova O, Kalinskaya A, Lebedeva A, Lysenko M, Maryukhnich E, Misyurina E, Protsenko D, Rosin A, Sapozhnikova O, Sokorev D, Shpektor A, Vorobyeva D, Vasilieva E, Margolis L. Lebedeva A, et al. Among authors: lysenko m. Int J Mol Sci. 2022 Jul 19;23(14):7937. doi: 10.3390/ijms23147937. Int J Mol Sci. 2022. PMID: 35887283 Free PMC article.
Ruxolitinib versus dexamethasone in hospitalized adults with COVID-19: multicenter matched cohort study.
Stanevich OV, Fomina DS, Bakulin IG, Galeev SI, Bakin EA, Belash VA, Kulikov AN, Lebedeva AA, Lioznov DA, Polushin YS, Shlyk IV, Vorobyev EA, Vorobyeva SV, Surovceva TV, Bakulina NV, Lysenko MA, Moiseev IS. Stanevich OV, et al. Among authors: lysenko ma. BMC Infect Dis. 2021 Dec 22;21(1):1277. doi: 10.1186/s12879-021-06982-z. BMC Infect Dis. 2021. PMID: 34937556 Free PMC article.
[Criteria for the optimal use of interleukin-6 receptor blockers in patients with COVID-19].
Kruglova TS, Fomina DS, Poteshkina NG, Frolova NF, Beloglazova IP, Mutovina ZY, Samsonova IV, Kovalevskaja EA, Zagrebneva AI, Serdotetckova SA, Chernov AA, Lysenko MA. Kruglova TS, et al. Among authors: lysenko ma. Ter Arkh. 2021 Nov 15;93(11):1316-1324. doi: 10.26442/00403660.2021.11.201248. Ter Arkh. 2021. PMID: 36286654 Russian.
[Levilimab and baricitinib prescribing experience in outpatient COVID-19 patients' treatment].
Khripun AI, Starshinin AV, Antipova YO, Lysenko MA, Urozhaeva YV, Gavrilenko OF, Rusantsova NA, Tyazhelnikov AA, Tikhonovskaya EY, Okolot NV, Sokolova MV, Fomina DS, Simonova EN, Kruglova TS, Chernov AA, Zagrebneva AI. Khripun AI, et al. Among authors: lysenko ma. Ter Arkh. 2022 Jun 17;94(5):668-674. doi: 10.26442/00403660.2022.05.201676. Ter Arkh. 2022. PMID: 36286967 Russian.
[Efficacy and safety of regdanvimab in patients with mild/moderate COVID-19 and high risk of progression of the disease: a retrospective study in a short-term stay unit].
Markina UA, Fomina DS, Lebedkina MS, Kruglova TS, Chernov AA, Zagrebneva AI, Mutovina ZY, Karaulov AV, Alexeeva EI, Lysenko MA. Markina UA, et al. Among authors: lysenko ma. Ter Arkh. 2022 Jun 17;94(5):675-682. doi: 10.26442/00403660.2022.05.201690. Ter Arkh. 2022. PMID: 36286968 Russian.
[Pre-exposure prophylaxis of new COVID-19 coronavirus infection with tixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies].
Roppelt AA, Lebedkina MS, Chernov AA, Kruglova TS, Mukhina OA, Yukhnovskaya YD, Samedova FA, Mаrkina UA, Andrenova GV, Karaulov AV, Lysenko MA, Fomina DS. Roppelt AA, et al. Among authors: lysenko ma. Ter Arkh. 2023 Feb 24;95(1):78-84. doi: 10.26442/00403660.2023.01.202088. Ter Arkh. 2023. PMID: 37167118 Russian.
[Use of a combination of the virus-neutralizing monoclonal antibodies casirivimab and imdevimab for mild to moderate COVID-19 in patients at high risk of progression: Results of the non-interventional observational study].
Lebedkina MS, Fomina DS, Mutovina ZY, Mаrkina UA, Bogomolov PO, Chulanov VP, Lysenko MA, Alexeeva EI. Lebedkina MS, et al. Among authors: lysenko ma. Ter Arkh. 2023 Aug 17;95(6):494-499. doi: 10.26442/00403660.2023.06.202297. Ter Arkh. 2023. PMID: 38158969 Russian.
Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period.
Fomina DS, Lebedkina MS, Iliukhina AA, Kovyrshina AV, Shelkov AY, Andreev SS, Chernov AA, Dolzhikova IV, Kruglova TS, Andrenova GV, Tukhvatulin AI, Shcheblyakov DV, Karaulov AV, Lysenko MA, Logunov DY, Gintsburg AL. Fomina DS, et al. Among authors: lysenko ma. Front Immunol. 2023 Oct 20;14:1259725. doi: 10.3389/fimmu.2023.1259725. eCollection 2023. Front Immunol. 2023. PMID: 37928549 Free PMC article. Clinical Trial.
65 results